|Description||Fenobam is a potent, selective, noncompetitive glutamate mGluR5 receptor antagonist. It displays inverse agonist properties. It blocks mGluR5 constitutive activity in vitro with IC50 value of 87 nM. It has been used as a lead compound for the development of a range of newer mGluR5 antagonists. It has also shown promising initial results in the treatment of fragile X syndrome. It also displays anxiolytic activity. It was developed by Johnson & Johnson and in clinic phase 2 trials with no progress.|
|Solubility||DMSO: >20 mg/mL|
|Application||Fenobam has been used as a lead compound for the development of a range of newer mGluR5 antagonists. It has also shown promising initial results in the treatment of fragile X syndrome. It also displays anxiolytic activity.|
|Quality Standard||In-house standard|
|Quantity||Grams to Kilograms|
|Density||1.47±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Fenobam was developed by Johnson & Johnson and in clinic phase 2 trials with no progress.|
MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM, exhibiting no appreciable activity at mGlu1b/2/3/4a/7b/8a/6 receptors.
LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II su...
Raseglurant is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP. It can be used for the treatment of migraine, gastroesophageal refl...
Topiramate is a kainate GluR5 receptor antagonist,originally used as an anticonvulsant.
TCN238 is an orally available, brain penetrant and positive allosteric mGlu4 receptor modulator (EC50= 1 μM) with 30-fold selectivity over mGluR5 using human re...
CPPHA is a selective positive allosteric modulator of mGluR5 receptor. It is thought to act at a novel allosteric site and potentiates mGlu5 responses by a mech...
Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease.
Lu AF21934 is a selective and brain-penetrating positive allosteric modulator (PAM) of mGlu4 receptors (IC50= 500 nM) on the harmaline-induced tremor and other ...
ML337 is a Selective negative allosteric modulator of mGlu3 with IC50 value of 593 nM. It shows no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 3...
RG7090 is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5).
Potent and selective antagonist for metabotropic glutamate receptor subtype 5 (mGluR5); Systemically active in vivo.
Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist (IC50=30 nM), as a a selective non-competitive antagonist.
FITM is a potent mGlu1 inhibitor (Ki = 2.5 nM) with great selectivity that does not disrupt mGlu5.
Methoxy-PEPy is a potent and highly selective mGlu5 receptor antagonist.
Glutamate, the major excitatory neurotransmitter in the brain, acts on both ionotropic and metabotropic glutamate receptors. Excessive metabotropic glutamate re...
L-Glutamine is one of the 20 amino acids encoded by the standard genetic code.
BAY 36-7620 elective mGlu1 receptor non-competitive antagonist (IC50 = 0.16 μM) with inverse agonist activity.
JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.
VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes.